Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities
Pittsboro, NC – July 13th, 2023
Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, is proud to announce growth and new capabilities to further enhance its position in the industry. In July 2023, Xyzagen expanded its talented team with the hire of David Fischler, PhD and introduced capabilities in peptide Liquid Chromatography-Mass Spectrometry (LC-MS) capabilities to better serve its clients and accelerate scientific breakthroughs in the early discovery phase.
“We are excited to welcome exceptional new talent to Xyzagen and to expand our LC-MS/MS capabilities into small peptide analysis,”
said Christopher Crean, CEO and Founder of Xyzagen. “The additional scientific expertise and additional bioanalytical capabilities to our wet lab will create efficiencies being adjacent to our animal vivarium, for turnkey nonclinical studies and standalone pharmacokinetics/sample analysis in that early discovery phase of drug development.”
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen accelerates early-phase drug development through its proprietary First-in-Rat® and First-in-Mouse® discovery platforms. The company also supports late-stage clinical pharmacokinetics, population PK modeling, and quantitative medicine.
Xyzagen’s boutique structure ensures personalized, expert collaboration with small clients during critical stages of drug development, from candidate selection to pre-NDA meetings.
